Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ADSS2 | P30520 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13234931 | 1.00 | POLA1 (0.44) | POLA1POLBP2RY2P2RY6P2RY4 | |
| SCHEMBL12354843 | 1.00 | POLA1 (0.44) | POLA1POLBP2RY2P2RY6P2RY4 | |
| SCHEMBL12363580 | 1.00 | POLA1 (0.44) | POLA1POLBP2RY2P2RY6P2RY4 | |
| SCHEMBL18394211 | 0.90 | P2RY2 (0.51) | POLBP2RY2P2RY6P2RY4 | |
| SCHEMBL13815856 | 0.87 | POLA1 (0.38) | POLA1POLBP2RY2P2RY6P2RY4 | |
| SCHEMBL4248196 | 0.87 | FGFR1 (0.39) | POLA1POLBP2RY2P2RY6P2RY4 | |
| SCHEMBL13805632 | 0.87 | POLA1 (0.38) | POLA1POLBP2RY2P2RY6P2RY4 | |
| Phosphoric Acid SCHEMBL17027889 | 0.86 | LMNA (0.47) | POLA1POLBP2RY2TSHRLMNA | |
| Phosphoric Acid SCHEMBL18438955 | 0.86 | LMNA (0.47) | POLA1POLBP2RY2TSHRLMNA | |
| SCHEMBL9515900 | 0.85 | POLB (0.43) | POLA1POLBP2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120064427-A | Method and analysis system for detecting brain nucleic acid hydrolysate spatial distribution based on mass spectrum imaging | 北京脑科学与类脑研究所 | 2025-05-30 | — | — | CN | claimed |
| CN-106232834-B | Sample preparation method | 牛津纳米孔技术公司 | 2020-09-22 | — | — | CN | claimed |
| EP-3108010-B1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECH LTD (GB) | 2018-11-28 | — | — | EP | claimed |
| EP-3108010-A1 | SAMPLE PREPARATION METHOD | Oxford Nanopore Technologies Limited (GB) | 2016-12-28 | — | — | EP | claimed |
| CN-106232834-A | Sample preparation methods | 牛津纳米孔技术公司 | 2016-12-14 | — | — | CN | claimed |
| WO-2015124935-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-08-27 | — | — | WO | claimed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| CN-120064427-A | Method and analysis system for detecting brain nucleic acid hydrolysate spatial distribution based on mass spectrum imaging | 北京脑科学与类脑研究所 | 2025-05-30 | — | — | CN | disclosed |
| US-20230250474-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-10 | — | — | US | disclosed |
| US-11542551-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-01-03 | — | — | US | disclosed |
| US-20200318179-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2020-10-08 | — | — | US | disclosed |
| CN-106232834-B | Sample preparation method | 牛津纳米孔技术公司 | 2020-09-22 | — | — | CN | disclosed |
| US-10669578-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2020-06-02 | — | — | US | disclosed |
| EP-3108010-B1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECH LTD (GB) | 2018-11-28 | — | — | EP | disclosed |
| US-20170067101-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2017-03-09 | — | — | US | disclosed |
| EP-3108010-A1 | SAMPLE PREPARATION METHOD | Oxford Nanopore Technologies Limited (GB) | 2016-12-28 | — | — | EP | disclosed |
| CN-106232834-A | Sample preparation methods | 牛津纳米孔技术公司 | 2016-12-14 | — | — | CN | disclosed |
| WO-2015124935-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | POLA1 19/4885POLB 4/4885P2RY2 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.